What Is the Difference Between Strep A and Strep B?

Strep A and Strep B are both members of the streptococcus family, but they are different bacterial species that cause very different diseases in very different people. Strep A (Streptococcus pyogenes) is the one behind strep throat, scarlet fever, and certain dangerous skin infections, primarily in children and otherwise healthy adults. Strep B (Streptococcus agalactiae) lives harmlessly in the gut and genital tract of many adults but becomes a serious threat when passed from mother to newborn during birth, causing sepsis and meningitis in the first weeks of life. The confusion between them is understandable because their names sound like they belong on a spectrum, but in practice they target different populations, trigger different immune problems, and require completely different prevention strategies.

Where the “A” and “B” Come From

The letter labels date back to a classification system developed by the microbiologist Rebecca Lancefield, who sorted streptococcal bacteria into groups based on differences in a sugar molecule embedded in their cell walls. Each group carries a distinct version of this carbohydrate antigen, and the system ultimately identified twenty groups labeled A through V (skipping I and J).¹ The grouping proved enormously useful because bacteria within each group tend to cause a recognizable pattern of disease, and it remains the foundation for how clinicians think about streptococcal infections today.² Groups C and G cause their own set of infections, but A and B are the two that matter most in everyday medicine.

Strep A and the Diseases It Causes

Strep A is one of the most versatile human pathogens around. It colonizes the throat and skin, and infections range from the common and self-limiting to the rare and life-threatening.³ Most people encounter it as strep throat (pharyngitis) or as a skin infection like impetigo or cellulitis.⁴ These infections are uncomfortable but generally respond quickly to antibiotics. The trouble is that Strep A does not always stay in these lanes.

In its most aggressive form, Strep A can invade deep tissue and the bloodstream, causing necrotizing fasciitis (the “flesh-eating” infection that makes headlines), severe muscle infections, and streptococcal toxic shock syndrome. Death rates for these invasive infections are sobering, ranging from roughly one in five for necrotizing fasciitis to nearly all cases of deep muscle infection if treatment is delayed.⁵ What makes Strep A so dangerous in these scenarios is its arsenal of secreted toxins. It produces enzymes that destroy tissue, proteins that punch holes in cell membranes, and superantigens that hijack the immune system into an overwhelming inflammatory response.⁶ Those superantigens are the driving force behind toxic shock, essentially short-circuiting the body’s immune regulation so that the response itself becomes the threat.

Autoimmune Complications Unique to Strep A

One of the most distinctive and troubling features of Strep A is what can happen after the infection clears. In a small fraction of people, the immune system’s response to the bacterium misfires and begins attacking the body’s own tissues. Rheumatic fever, which can permanently damage heart valves, and post-streptococcal glomerulonephritis, which inflames the kidneys, are the two classic autoimmune consequences.⁷ Rheumatic fever in particular is a textbook example of autoimmunity triggered by infection, and the mechanism involves parts of the Strep A bacterium looking similar enough to human heart tissue that the immune system gets confused.⁸

A more controversial post-streptococcal condition is PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections), in which children develop sudden-onset obsessive-compulsive symptoms or tics after a Strep A infection. Not all researchers accept that this is a distinct entity, and the debate continues.⁸ What is not in dispute is that Strep A’s ability to trigger autoimmune damage to the heart and kidneys makes prompt antibiotic treatment of strep throat more important than it might seem for a simple sore throat. Strep B, by contrast, does not cause these post-infectious immune syndromes.

Strep B and the Diseases It Causes

Strep B inhabits a completely different ecological niche. It lives as a normal part of the gut and vaginal flora in a substantial proportion of healthy adults. Globally, roughly one in five women carry it in the lower genital tract without any symptoms at all.⁹ For the colonized person, Strep B is typically harmless. The danger arises during childbirth, when the bacterium can be transmitted to the baby as it passes through the birth canal.

Neonatal Strep B disease comes in two forms. Early-onset disease strikes within the first week of life, usually presenting as pneumonia or sepsis. Late-onset disease, which occurs between about one week and three months of age, more often causes meningitis.¹⁰ Both are medical emergencies. The introduction of routine prenatal screening and antibiotics given during labor has dramatically reduced early-onset cases, which means late-onset infections now make up a larger share of neonatal Strep B disease.¹¹

Strep B in Adults Outside of Pregnancy

While neonatal disease gets the most attention, Strep B also causes serious infections in older adults and people with chronic health conditions. Skin and soft-tissue infections, bloodstream infections without a clear source, bone infections, urinary sepsis, and pneumonia are the most common presentations.¹² The people most at risk tend to have diabetes, liver disease, cancer, or neurological conditions that compromise their defenses.¹³ This is an underappreciated side of Strep B, and the burden in elderly populations appears to be growing.

Different Tricks for Evading the Immune System

One of the most fundamental biological differences between these two bacteria is how they survive inside a human host. Strep A takes an aggressive, offensive approach. It floods the surrounding environment with dozens of toxins and enzymes that break down tissue, dissolve blood clots, and overwhelm the immune system with superantigen-driven inflammation.⁶ The strategy is essentially a full-frontal assault that destroys host tissue while distracting the immune response.

Strep B takes a subtler, stealthier path. Its key weapon is a thick sugar capsule that coats the outside of the cell. Early experiments showed that removing this capsule made the bacterium dramatically less dangerous in animal models.¹⁴ The capsule works in part because it is decorated with sialic acid, a sugar molecule that also sits on the surface of human cells. This molecular mimicry tricks immune cells into treating the bacterium as if it belongs there. When the sialic acid coating was stripped away experimentally, Strep B lost much of its ability to resist killing by the immune system.¹⁵ Specific genes are required to build this capsule, and knocking them out severely reduces capsule production.¹⁶

So where Strep A overwhelms, Strep B hides. This difference in strategy explains a lot about the clinical pictures: Strep A infections tend to be acutely inflammatory and tissue-destructive, while Strep B infections, especially in newborns, involve the bacterium quietly multiplying in the blood or cerebrospinal fluid before the immature immune system can mount an adequate response.

How Each Is Diagnosed

The diagnostic approach for Strep A and Strep B differs as much as the diseases themselves. For Strep A, the situation that comes up most often is a child or adult with a sore throat. The standard first step is a rapid antigen detection test, the familiar “rapid strep test” done with a throat swab in the clinic. Modern versions of these tests are quite accurate, with one recent evaluation finding sensitivity above 98% and specificity above 96% compared to throat culture.¹⁷ Throat culture remains the gold standard when a rapid test comes back negative but suspicion is high, and molecular methods like PCR are also available in some settings.¹⁸

Strep B testing works differently because you are not usually diagnosing an active infection. Instead, the goal is to screen pregnant women for colonization so that antibiotics can be given during labor. Current guidelines recommend collecting vaginal and rectal swabs at 35 to 37 weeks of pregnancy and culturing them for Strep B.¹⁹ Newer molecular techniques and specialized culture media have improved detection, but screening still misses a small percentage of carriers because colonization status can fluctuate in the weeks between the test and delivery.²⁰ One large study found that late-pregnancy culture had about 89% sensitivity for predicting colonization at the time of labor, while intrapartum PCR reached about 92%.²¹

Preventing Strep B in Newborns

Because Strep B colonization is common and usually symptom-free in the mother, the prevention strategy centers on giving intravenous antibiotics (typically penicillin) during labor to women who tested positive. This intrapartum antibiotic prophylaxis has been remarkably effective. In one study, it was about 84% effective at preventing mother-to-newborn transmission of the bacterium.²² A meta-analysis comparing universal screening programs to risk-based approaches (where antibiotics are given only if a woman has certain risk factors like preterm labor or fever) found that screening-based strategies cut the rate of early-onset Strep B disease by more than half compared to risk-based protocols, without significantly increasing overall antibiotic use.²³

In settings where universal screening is not feasible, selective screening based on risk factors like preterm delivery or urinary tract infection during the current pregnancy can serve as a reasonable fallback.²⁴ No comparable screening program exists for Strep A, because its infections are acute and symptomatic rather than arising from silent colonization before a high-risk event.

Antibiotic Resistance Patterns

Both Strep A and Strep B remain susceptible to penicillin, which is good news since penicillin is the first-line treatment for both. No clinically significant penicillin resistance has been documented in either species. The problem, as with many bacteria, lies with the backup antibiotics used when a patient is allergic to penicillin.

For Strep B, erythromycin and clindamycin are the main alternatives, and resistance to both has risen sharply. One study of Strep B isolates from invasive infant infections found that erythromycin resistance jumped from about 4% in strains collected before 2000 to over 32% in strains collected after 2000; clindamycin resistance rose from roughly 2% to about 18% over the same period.²⁵ A separate study found erythromycin resistance in 22% of Strep B isolates, with different resistance genes conferring different patterns of cross-resistance to clindamycin.²⁶ In some regions, rates are even higher; a study of isolates in Beijing found erythromycin resistance topping 85%.²⁷ The practical consequence is that when a penicillin-allergic woman needs intrapartum prophylaxis, her Strep B isolate should be tested for clindamycin susceptibility rather than assuming it will work.

The Search for Vaccines

Neither Strep A nor Strep B has an approved vaccine, but both are the subject of active research, and the approaches look quite different.

Strep A vaccine development has been notoriously difficult. The M protein on the surface of the bacterium is the most obvious vaccine target, but it comes in over 200 types, and early vaccine attempts in the 1960s raised concerns about triggering the same autoimmune reactions (like rheumatic fever) that the bacterium itself causes. Modern candidates have moved toward multivalent M protein vaccines and combination vaccines using multiple shared antigens that can provide broader protection. Several candidates have reached early-stage human trials, and newer formulations with improved immune-boosting ingredients are showing promise in animal models.²⁸ The global toll of Strep A disease, estimated at over 639,000 deaths annually, most of them from rheumatic heart disease, adds urgency to this effort.²⁹

Strep B vaccine strategy takes a different tack. Because the most devastating disease occurs in newborns, the idea is to vaccinate pregnant women so that protective antibodies cross the placenta and shield the baby during its most vulnerable weeks.³⁰ The leading candidates target the sugar capsule that is Strep B’s main defense. One of the furthest-along candidates, a hexavalent capsular polysaccharide vaccine developed by Pfizer, entered phase 3 trials in 2023.³¹ Protein-based vaccines that could protect against all Strep B serotypes are also in development.³² A successful Strep B vaccine could eventually replace or supplement the current approach of screening and intrapartum antibiotics, which would be especially valuable in low-resource settings where universal screening is impractical.

Why Some People Get Sicker Than Others

One question that comes up with both infections is why the same bacterium causes a mild sore throat in one person and a life-threatening invasive infection in another. The bacterium’s own characteristics matter, particularly which toxins and virulence factors a given strain carries, but host genetics play a significant role as well.

For Strep A, research has found that variations in the immune-system genes known as HLA class II alleles influence how strongly a person’s immune cells react to streptococcal superantigens. People carrying certain HLA variants mount a more restrained immune response to these superantigens and are less likely to develop severe systemic disease, while other variants are associated with the runaway inflammatory response that drives toxic shock.³³ A separate study identified one specific HLA allele that roughly doubled the risk of invasive Strep A disease.³⁴ This is not information that changes clinical decisions right now, but it helps explain why seemingly healthy people sometimes develop devastating streptococcal infections out of nowhere.

Other Streptococcal Groups Worth Knowing About

Groups A and B get the spotlight, but they are not the only streptococci that cause human disease. Groups C and G streptococci, now often classified under the species name Streptococcus dysgalactiae, are closely related to Strep A and can cause similar types of infection including pharyngitis, cellulitis, and bloodstream infections.³⁵ They share enough biological characteristics with Strep A that a rapid strep test designed for Group A will not detect them, which is one reason a person with a genuine streptococcal pharyngitis can get a negative rapid test. Group D streptococci, particularly the enterococci that were once classified in this group, are important in hospital-acquired infections but inhabit a different clinical world entirely. Understanding that “strep” is not one bacterium but a family with distinct members helps make sense of why your doctor might say “your strep test is negative” even when your throat looks infected — they tested for one specific group, and another member of the family might be responsible.